Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required.
Swift, P A
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. [electronic resource] - International journal of clinical practice Sep 2010 - 1331-3 p. digital
Publication Type: Editorial; Comment
1742-1241
10.1111/j.1742-1241.2010.02472.x doi
Angiotensin Receptor Antagonists--therapeutic use
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Diabetic Nephropathies--prevention & control
Humans
Kidney Diseases--prevention & control
Renin-Angiotensin System--drug effects
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. [electronic resource] - International journal of clinical practice Sep 2010 - 1331-3 p. digital
Publication Type: Editorial; Comment
1742-1241
10.1111/j.1742-1241.2010.02472.x doi
Angiotensin Receptor Antagonists--therapeutic use
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Diabetic Nephropathies--prevention & control
Humans
Kidney Diseases--prevention & control
Renin-Angiotensin System--drug effects